This is a preview of subscription content, log in via an institution to check access.
Notes
2014 euros
Reference
Ruggeri M, et al. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy. Applied Health Economics and Health Policy : 14 Feb 2017. Available from: URL: http://doi.org/10.1007/s40258-017-0311-4
Rights and permissions
About this article
Cite this article
Tenofovir most cost effective for chronic hepatitis B in Italy. PharmacoEcon Outcomes News 772, 34 (2017). https://doi.org/10.1007/s40274-017-3782-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3782-5